|
Alonso-Navarro R, Ramirez M, Masia M, Paredes R, Montejano R, Povar-Echeverria M, Carratala J, Salavert M, Bernal E, Duenas C, Flores J, Fanjul F, Gutierrez I, Rico V, Mateu L, Cadinanos J, Berenguer J, Soriano A. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses. BMC Infect Dis. 2023 May 4;23(1):286. doi: 10.1186/s12879-023-08222-y. PubMed PMID: 37142994; PubMed Central PMCID: PMC10157565.
AÑO: 2023; IF: 3.4
|
37142994
|
Alvarez H, Gutierrez-Valencia A, Marino A, Saborido-Alconchel A, Calderon-Cruz B, Perez-Gonzalez A, Alonso-Dominguez J, Martinez-Barros I, Gallego-Rodriguez M, Moreno S, Aldamiz T, Montero-Alonso M, Bernal E, Galera C, Llibre JM, Poveda E. IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors. Front Immunol. 2023 Oct 18;14:1257725. doi: 10.3389/fimmu.2023.1257725. eCollection 2023. PubMed PMID: 37920466; PubMed Central PMCID: PMC10619723.
AÑO: 2023; IF: 5.7
|
|
Del Pozo-Valero M, Corton M, Lopez-Rodriguez R, Mahillo-Fernandez I, Ruiz-Hornillos J, Minguez P, Villaverde C, Perez-Tomas ME, Barreda-Sanchez M, Mancebo E; STOP_Coronavirus Study Group; Paz-Artal E, Guillen-Navarro E, Almoguera B, Ayuso C. Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years. Geroscience. 2023 Feb;45(1):543-553. doi: 10.1007/s11357-022-00666-5. Epub 2022 Oct 3. PubMed PMID: 36184726; PubMed Central PMCID: PMC9527133.
AÑO: 2023; IF: 5.3
|
|
Suarez-Garcia I, Alejos B, Hernando V, Vinuela L, Vera Garcia M, Rial-Crestelo D, Perez Elias MJ, Albendin Iglesias H, Peraire J, Tiraboschi J, Diaz A, Moreno S, Jarrin I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. PubMed PMID: 37099559; PubMed Central PMCID: PMC10232237.
AÑO: 2023; IF: 3.9
|
|
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masia M, Fanciulli C, Hernandez C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadella M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. PubMed PMID: 37725999.
AÑO: 2023; IF: 3.9
|